In support of World COPD Day on November 19, the Global Initiative for Chronic Obstructive Lung Disease (GOLD), is drawing attention to the importance of correctly diagnosing COPD earlier - with the ...
Please provide your email address to receive an email when new articles are posted on . Hospitalizations with vs. without pathway use were shorter and cost less. Significantly more ...
Independent news. Trusted by Texans. About The Texas Tribune | Staff | Contact | Send a Confidential Tip | Ethics | Republish Our Work | Jobs | Awards | Corrections | Strategic Plan | Downloads | ...
AJMC®: How is COPD definitively diagnosed in clinical practice, and how does this disease create a clinical burden on patients and caregivers? Dr Rali: COPD diagnosis requires both clinical context ...
GSK’s antibody-drug conjugate strategy may be making more headlines recently, but the British pharma hasn’t forgotten about oligonucleotides. The drugmaker is paying $85 million upfront to Empirico ...
Mepolizumab significantly reduced the annualized rate of moderate or severe exacerbations in COPD with an eosinophilic phenotype. Some 20% to 40% of COPD patients have elevated blood eosinophil counts ...
After another swing and a miss for AstraZeneca's Fasenra in chronic obstructive pulmonary disease (COPD), the company is pivoting to other options in its portfolio that might have potential to treat ...
Chronic obstructive pulmonary disease, or COPD, is the fourth leading cause of death worldwide, responsible for 3.5 million deaths in 2021, according to the World Health Organization. It’s a common ...
The 5 variables indicating whether azithromycin is likely to prevent AECOPD are white BCC, hemoglobin, CRP, FVC, and respiratory symptoms identified by the SGRQ. An individual treatment effect (ITE) ...
Investigators compare efficacy of low- versus high-dose of methylprednisolone in preventing pulmonary lesions in children with severe Mycoplasma pneumoniae pneumonia Mycoplasma pneumoniae infection is ...
Roche’s hopes of getting its chronic obstructive pulmonary disease (COPD) drug astegolimab to regulators this year have taken a hit after the anti-ST2 monoclonal antibody failed to reduce flare-ups in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results